Landscapes / Companies
Servier Bio-Innovation LLC not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
6
in active trials · 9 in all
Trials
5 active
9 since 2021
Drugs6
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Isocitrate dehydrogenase 1 inhibitor |
Approved | 15 Oct 2027Phase 3 trial completes | |||
| Next date | 15 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Leukemia, Myeloid, Acute, Cholangiocarcinoma and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer (NSCLC) | ||||
| Open drug page | |||||
— |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer and 1 more | ||||
| Open drug page | |||||
— |
Symphogen A/S |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer (NSCLC) | ||||
| Open drug page | |||||
— |
Phase 1/2 | 1 May 2027Phase 1/2 trial completes | |||
| Next date | 1 May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | MTAP-deleted Solid Tumors | ||||
| Open drug page | |||||
— |
Tango Therapeutics |
Phase 1/2 | 1 May 2027Phase 1/2 trial completes | ||
| Next date | 1 May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | MTAP-deleted Solid Tumors | ||||
| Open drug page | |||||
About
- No active trial
- PRS-344/S095012, S227928, Vorasidenib
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021